Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest announcement is out from Onco-Innovations Ltd. ( (TSE:ONCO) ).
Onco-Innovations Limited has announced promising results from its licensed technology of PNKP inhibitors, which enhance the effectiveness of chemotherapy by making cancer cells more sensitive to topoisomerase I poisons. This advancement could improve patient outcomes by directly inhibiting cancer cells’ ability to repair DNA, thereby addressing a key challenge in cancer treatment. The technology holds potential to significantly impact the global cancer therapy market as Onco-Innovations continues to innovate in overcoming drug resistance and enhancing cancer treatment efficacy.
More about Onco-Innovations Ltd.
Onco-Innovations Limited is a company in the biotechnology industry focusing on developing advanced cancer therapies. Their primary technology involves Polynucleotide Kinase 3′-Phosphatase (PNKP) inhibitors aimed at enhancing chemotherapy effectiveness by overcoming cancer cell resistance. The company is positioning itself as a significant player in the global cancer therapy market.
YTD Price Performance: 123.53%
Average Trading Volume: 401,259
See more insights into ONCO stock on TipRanks’ Stock Analysis page.
